Are there any circumstances you would not recommend sentinel lymph node biopsy in a breast cancer patient?

It is clear that we are moving away from aggressive axillary surgery for patients with minimal axillary disease given that no survival or axillary recurrence benefit (ACOSOG Z11, AMAROS) and increased risks of functional morbidities have been identified with completion axillary dissection. Naturally...